Healthcare · Drug Manufacturers - Specialty & Generic
Made onAug 25, 2026
Price at call$76.76
6-month call Bull +14.4%
Target by Feb 2027$87.80
Great value below$72.00
Modelv0.6.0
Projection vs Actual
(6M history + forecast)
The masterbrain's trajectory (blue, curved through its 7 checkpoints), the deterministic v0.3 control (dashed), and the actual price (green) overlaid from the prediction date forward.
Forecast Change+14.4% to $87.80
Predicted High$87.80at 6 months
Predicted Low$77.40in 2 weeks
Forecast
The masterbrain trajectory — 7 dated checkpoints. Short rungs (2w, 1m) show the typical range as the primary claim; point calls run from 2 months out. Every claim still gets graded.
Predicted Aug 25, 2026 1:03 pm
Bull
ZTS trends higher to
$87.80
(+14.4% from $76.76)
by Feb 2027.
dip-then-recover
ThesisZTS is a beaten-down defensive quality name (-39% trailing 6mo) trading well below composite fair value of $105. With regulatory wins, a Burry-branded contrarian narrative, and no near-term earnings risk, expect a gradual mean-reversion toward the deterministic $87 baseline, front-loaded by sentiment stabilization then value gravity.
Invalidated ifBreak below $72 attractive-value line with continuation to bear scenario $59, or a surprise guide cut breaking the defensive thesis.
Checkpointtime after the call
Datewhen it gets graded
Predictedthe claim: closing price
Current priceactual close — fills in over time
Predicted returnpredicted vs $76.76 at call
Conv.brain's confidence, 1–10
Driverwhy the brain put the point here
Prediction made
Aug 25, 2026
—
$76.76at call
—
—
The anchor — every point below is measured from this price and date.
2 weeks
Sep 8, 2026
$71.76–$81.76typical range · internal point $77.40
—
±6.5%
6/10
Oversold defensive stabilizes near current with low vol
What actually happened:
closed $75.81
on Sep 4, 2026 = -1.2% vs the call
(predicted +0.8%)
· direction HIT
(called flat, was flat)
· off by 2.1 pp
· accuracy 9/10
· typical range ±6.5%:
inside the band
· S&P +0.5%
over the same window — lagged it
1 month
Sep 25, 2026
$69.52–$84.00typical range · internal point $78.90
—
±9.4%
6/10
Contrarian bid builds on Burry narrative and regulatory tailwind
What actually happened:
closed $70.27
on Sep 24, 2026 = -8.5% vs the call
(predicted +2.8%)
· direction MISS
(called flat, was down)
· off by 11.2 pp
· accuracy 4/10
· typical range ±9.4%:
inside the band
· S&P +0.4%
over the same window — lagged it
2 months
Oct 25, 2026
$81.20
—
+5.8%
5/10
Mean reversion continues as sentiment overhang lifts
Why ranges on the short rungs?
A 102-prediction trial (2026-07-21) showed 2-week point calls carry no information here —
three prompt formulations all lost to simply predicting zero — while the stock's own
volatility scale (σ×√t) described those windows well. So the short rungs claim what's
actually knowable: the typical travel, with earnings timing flagged where the variance
will come from. The internal point calls keep being generated and graded to map where
real skill begins. Full evidence: stocks/predictions/V0.5-DESIGN.md §8.
Deterministic control (v0.3 value line) targets
$87.03
(+13.4%)
— both lines get graded at every checkpoint, so the brain has to beat the formula, not just replace it.
Brain: claude-opus-4-7.
Weaknesses
No weaknesses recorded for this run.
All inputs present, no fallbacks used — nothing to flag.
Equation Inputs
Everything feeding the v0.6.0 model — value anchors, the stock's own price behaviour, and the tunable knobs.
Value anchors (from deep analysis)
Price at call
$76.76
Composite fair value
$105.34
Signal-adjusted fair value
$120.05
DCF fair value
$80.37
Anchored-PE fair value
$167.71
Buy-below (value lens)
$72.00
Value net score
+31
Value confidence
6 / 10
Quality net score
+69
Memo confidence
7 / 10
Deserved value (base)
—
Quality tilt
—
Deserved value (used)
—
Coherence (value × quality)
—
Price behaviour (trailing — shapes the realism line)